Foley & Lardner’s Dallas Office Announces Three New Partners: Christopher J. Babcock, Thomas Scannell and Dovi Adlerstein
02 February 2021
D Magazine
Just recently, 19 Foley & Lardner employees were promoted, including the transition of two senior counsels and one counsel to partner roles at the Dallas office.
Christopher J Babcock previously served as a senior counsel, focusing on private equity, corporate governance, and securities matters. He also represented clients across a broad range of corporate governance and capital market matters, including tender offers, public exchange offers, and more.
Thomas Scannell also served as senior counsel in the firm’s restructuring and reorganization practice. His focus is the restructuring of companies in and out of bankruptcy, debtors’ and creditors’ rights, and debtor-in-possession financers.
Dovi Adlerstein served as counsel and a business lawyer. His specialties include structuring, negotiating, and implementing all phases of mergers and acquisitions, corporate recapitalizations, and private equity transactions.
Christopher J Babcock previously served as a senior counsel, focusing on private equity, corporate governance, and securities matters. He also represented clients across a broad range of corporate governance and capital market matters, including tender offers, public exchange offers, and more.
Thomas Scannell also served as senior counsel in the firm’s restructuring and reorganization practice. His focus is the restructuring of companies in and out of bankruptcy, debtors’ and creditors’ rights, and debtor-in-possession financers.
Dovi Adlerstein served as counsel and a business lawyer. His specialties include structuring, negotiating, and implementing all phases of mergers and acquisitions, corporate recapitalizations, and private equity transactions.
People
Related News
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."
08 October 2024
In the News
Anil Shankar Shares Insight on Proposition 34, Impact to 340B Program
Foley & Lardner LLP partner Anil Shankar offered insight on California's Proposition 34, a ballot measure this election season, in the KCRW article, "Confused on Prop 34? It’s about the politics of rent control."